Friday, July 10, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Clinical program

219590

Phase 2 · small molecule · Neoplasms

219590 for Neoplasms is a Phase 2 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

← All GlaxoSmithKline projects Phase 2 small molecule active

Internal code 219590

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GlaxoSmithKline
Phase
Phase 2
Modality
small_molecule
Indication
Neoplasms
Status
active
Trials
1